Literature DB >> 9636057

Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors.

E Komorowicz1, K Kolev, R Machovich.   

Abstract

Quantitative characterization of the interaction of des-kringle1-5-plasmin (microplasmin) with fibrin(ogen) and plasma protease inhibitors may serve as a tool for further evaluation of the role of kringle domains in the regulation of fibrinolysis. Comparison of fibrin(ogen) degradation products yielded by plasmin, miniplasmin (des-kringle1-4-plasmin), microplasmin, and trypsin on SDS gel electrophoresis indicates that the differences in the enzyme structure result in different rates of product formation, whereas the products of the four proteases are very similar in molecular weight. Kinetic parameters show that plasmin is the most efficient enzyme in fibrinogen degradation, and the kcat/KM ratio decreases in parallel with the loss of the kringle domains. The catalytic sites of the four proteases have similar affinities for fibrin (KM values between 0.12 and 0.21 microM). Trypsin has the highest catalytic constant for fibrin digestion (kcat = 0.47 s-1), and among plasmins with different kringle structures, the loss of kringle5 results in a markedly lower catalytic rate constant (kcat = 0.0076 s-1 for microplasmin vs 0.048 s-1 for miniplasmin and 0.064 s-1 for plasmin). In addition, microplasmin is inactivated by plasmin inhibitor (k" = 3.9 x 10(5) M-1 s-1) and antithrombin (k" = 1.4 x 10(3) M-1 s-1) and the rate of inactivation decreases in the presence of fibrin(ogen). Heparin (250 nM) accelerates the inactivation of microplasmin by antithrombin (k" = 10.5 x 10(3) M-1 s-1 ), whereas that by plasmin inhibitor is not affected (k" = 4.2 x 10(5) M-1 s-1).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636057     DOI: 10.1021/bi980180d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator.

Authors:  Paul Y Kim; Long D Tieu; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

2.  Coagulation factor XIIIa is inactivated by plasmin.

Authors:  Woosuk S Hur; Nima Mazinani; X J David Lu; Heidi M Britton; James R Byrnes; Alisa S Wolberg; Christian J Kastrup
Journal:  Blood       Date:  2015-09-10       Impact factor: 22.113

3.  Proteolytic resistance conferred to fibrinogen by von Willebrand factor.

Authors:  A Tanka-Salamon; K Kolev; R Machovich; E Komorowicz
Journal:  Thromb Haemost       Date:  2009-12-18       Impact factor: 5.249

4.  Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones.

Authors:  Colin Longstaff; Imre Varjú; Péter Sótonyi; László Szabó; Michael Krumrey; Armin Hoell; Attila Bóta; Zoltán Varga; Erzsébet Komorowicz; Krasimir Kolev
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

5.  Hindered dissolution of fibrin formed under mechanical stress.

Authors:  I Varjú; P Sótonyi; R Machovich; L Szabó; K Tenekedjiev; M M C G Silva; C Longstaff; K Kolev
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

Review 6.  Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.

Authors:  Victor Gurewich
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

7.  Structure and Function of Trypsin-Loaded Fibrinolytic Liposomes.

Authors:  Anna Tanka-Salamon; Attila Bóta; András Wacha; Judith Mihály; Miklós Lovas; Krasimir Kolev
Journal:  Biomed Res Int       Date:  2017-07-03       Impact factor: 3.411

8.  Suppressed catalytic efficiency of plasmin in the presence of long-chain fatty acids. Identification of kinetic parameters from continuous enzymatic assay with Monte Carlo simulation.

Authors:  Anna Tanka-Salamon; Kiril Tenekedjiev; Raymund Machovich; Krasimir Kolev
Journal:  FEBS J       Date:  2008-02-12       Impact factor: 5.542

9.  Purification and characterization of mutant miniPlasmin for thrombolytic therapy.

Authors:  Xiaotao Lin; Yan Wang; Yanwen Zhang; Bing Huang; James J Lin; Scott J Hallock; Hong Yu; Hongwei Shao; Jing Yan; Bo Huang; Xuejun C Zhang; Wei Cao; Xueming Xu; Xinli Lin
Journal:  Thromb J       Date:  2013-01-30

Review 10.  The Fibrinolytic System: Mysteries and Opportunities.

Authors:  Robert L Medcalf; Charithani B Keragala
Journal:  Hemasphere       Date:  2021-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.